July 31, 2017
Kyowa Hakko Kirin racked up higher profits on higher sales in the first half of 2017, buoyed by licensing revenues tied to benralizumab from AstraZeneca and lower R&D outlays, the company said on July 28. In January-June, the drug maker’s...read more